PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 12, 2016

Study Completion Date

September 12, 2016

Conditions
Cholangiocarcinomas
Interventions
DRUG

Cisplatin, Gemcitabine, Panitumumab

Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1

DRUG

Cisplatin, Gemcitabine

Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8

Trial Locations (16)

13353

Charité Berlin, Berlin

20246

University Hospital Hamburg-Eppendorf, Hamburg

30625

Medical School Hannover, Hanover

35043

University Hospital Marburg, Marburg

39130

Magdeburg Hospital, Magdeburg

45122

University Hospital Essen, Essen

50924

University Hospital Köln, Cologne

55131

University Hospital Mainz, Mainz

68167

University Hospital Mannheim, Mannheim

69120

National Centre for Tumor Diseases (NCT), Heidelberg

72076

University Hospital Tuebingen, Tübingen

72764

Kreiskliniken Reutlingen GmbH, Reutlingen

73730

Esslingen Hospital, Esslingen am Neckar

79106

University Hospital Freiburg, Freiburg im Breisgau

81675

Klinikum rechts der Isar der TU München, München

93042

University Hospital Regensburg, Regensburg

All Listed Sponsors
lead

Hannover Medical School

OTHER

NCT01320254 - PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) | Biotech Hunter | Biotech Hunter